glp-1 agonist and heart failure receptor agonists cardiovascular outcome trials: An update GLP-1 agonists for heart failure:

doi: 10.3390/cells11030552

Rathinam, R., Ghosh, S., Neumann, W

Its primary actions include: Increasing slow-wave (delta) sleep the deepest, most physically restorative sleep stage Modulating corticotropin-releasing hormone (CRH) reducing the HPA axis signalling that keeps cortisol elevated Influencing LH and somatostatin release both relevant to testosterone and growth hormone secretion Antioxidant activity preclinical data suggests DSIP has direct free-radical scavenging properties (3) Thermoregulatory effects potentially lowering basal body temperature in a manner consistent with natural sleep onset The net effect is not sedation

Five flasks were used to dissolve various interfering biochemicals

Beauty from within has never tasted this good

Nat Commun 15(1):10714-